Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CNR2 | P34972 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135802 | 1.00 | NR5A1 (0.53) | NR5A1TSHRCNR2MEN1ALDH1A1 | |
| SCHEMBL3682775 | 1.00 | NR5A1 (0.53) | NR5A1TSHRCNR2MEN1ALDH1A1 | |
| SCHEMBL30775079 | 1.00 | NR5A1 (0.53) | NR5A1TSHRCNR2MEN1ALDH1A1 | |
| SCHEMBL2017497 | 0.91 | CNR2 (0.53) | NR5A1TSHRCNR2MEN1ALDH1A1 | |
| SCHEMBL17558102 | 0.89 | TSHR (0.47) | NR5A1TSHRCNR2MEN1ALDH1A1 | |
| SCHEMBL17558100 | 0.89 | TSHR (0.47) | NR5A1TSHRCNR2MEN1ALDH1A1 | |
| SCHEMBL17558130 | 0.88 | CNR2 (0.56) | TSHRCNR2MEN1ALDH1A1KMT2A | |
| SCHEMBL27088421 | 0.86 | TSHR (0.59) | NR5A1TSHRCNR2MEN1ALDH1A1 | |
| SCHEMBL25254779 | 0.86 | CNR2 (0.44) | NR5A1TSHRCNR2MEN1ALDH1A1 | |
| SCHEMBL25297144 | 0.86 | CNR2 (0.44) | NR5A1TSHRCNR2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353147-B2 | Method for producing peptide | AJINOMOTO CO., INC. (JP) | 2016-05-31 | — | — | US | claimed |
| US-9353148-B2 | Method for producing peptide | AJINOMOTO CO., INC. (JP) | 2016-05-31 | — | — | US | claimed |
| US-20140088291-A1 | METHOD FOR PRODUCING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2014-03-27 | — | — | US | claimed |
| US-20140080999-A1 | METHOD FOR PRODUCING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2014-03-20 | — | — | US | claimed |
| US-12351601-B2 | Method for producing peptide continuously | AJINOMOTO CO., INC. (JP) | 2025-07-08 | — | — | US | disclosed |
| WO-2025122535-A2 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | US | disclosed |
| CN-113039193-B | Method for producing cyclized peptide having intramolecular S-S bond | 味之素株式会社 | 2024-11-12 | — | — | CN | disclosed |
| US-11939404-B2 | Method for producing cyclized peptide having intramolecular S-S bond | AJINOMOTO CO., INC. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | AJINOMOTO CO., INC. (JP) | 2022-02-10 | — | — | US | disclosed |
| EP-3882255-A1 | METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND | AJINOMOTO CO., INC. (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-20210277063-A1 | METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND | AJINOMOTO CO., INC. (JP) | 2021-09-09 | — | — | US | disclosed |
| US-9353147-B2 | Method for producing peptide | AJINOMOTO CO., INC. (JP) | 2016-05-31 | — | — | US | disclosed |
| US-9353148-B2 | Method for producing peptide | AJINOMOTO CO., INC. (JP) | 2016-05-31 | — | — | US | disclosed |
| US-20140088291-A1 | METHOD FOR PRODUCING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140080999-A1 | METHOD FOR PRODUCING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | VIP, RNGTT, SSU72 | NR5A1 1636/4885TSHR 2281/4885CNR2 4682/4885 |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | VIP, NPPA, NGLY1 | NR5A1 2347/4885TSHR 1885/4885CNR2 4197/4885 |
| US-11939404-B2 | Method for producing cyclized peptide having intramolecular S-S bond | SPPL2B, PTMS, VIP | NR5A1 1233/4885TSHR 1502/4885CNR2 4671/4885 |
| US-20140080999-A1 | METHOD FOR PRODUCING PEPTIDE | VIP, ANPEP, NPPA | NR5A1 2972/4885TSHR 2603/4885CNR2 4329/4885 |
| US-20140088291-A1 | METHOD FOR PRODUCING PEPTIDE | ANPEP, NPPA, LNPEP | NR5A1 2104/4885TSHR 1168/4885CNR2 4129/4885 |
| US-12351601-B2 | Method for producing peptide continuously | VIP, NPPA, NGLY1 | NR5A1 2347/4885TSHR 1885/4885CNR2 4197/4885 |
| US-20210277063-A1 | METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND | SPPL2B, PTMS, VIP | NR5A1 1233/4885TSHR 1502/4885CNR2 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.